Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Shattuck Labs, Inc. (STTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights –Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer at the American Society of Clinical Oncology 2023 annual meeting, including data supporting 3 mg/kg as the appropriate dose for each PROC combination cohort –"
05/24/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights –Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer to be presented at the 2023 American Society of Clinical Oncology annual meeting in June –"
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates –Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –"
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in SHATTUCK LABS INC
12/08/2022 SC 13D/A Hornblower Josiah reports a 7% stake in SHATTUCK LABS, INC.
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights –Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer&#59; complete data expected midyear 2023 –"
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/01/2022 EFFECT Form EFFECT - Notice of Effectiveness:
07/29/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, between Shattuck Labs, Inc. and SVB Securities LLC",
"Opinion of Gibson, Dunn & Crutcher LLP"
07/29/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/28/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
06/10/2022 8-K Quarterly results
06/09/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
04/21/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/15/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/15/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2022 8-K Quarterly results
Docs: "Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights – Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients –"
03/15/2022 10-K Annual Report for the period ended December 31, 2021
02/14/2022 SC 13G/A EcoR1 Capital, LLC reports a 0% stake in Shattuck Labs, Inc.
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy